Advertisement
Advertisement
PLYX
Polaryx Therapeutics, Inc. Common Stock
2.02
USDSponsored
+0.01
+0.50%
Sep 14, 15:59 UTC -4
Closed
After-Market
2.03
+0.01
+0.45%
PLYX Earnings Reports
Positive Surprise Ratio
PLYX beat 1 of 1 last estimates.
100%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Polaryx Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, PLYX reported earnings of -0.03 USD per share (EPS) for Q2 26, beating the estimate of -0.04 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.00% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Polaryx Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Polaryx Therapeutics, Inc. Common Stock reported EPS of -$0.03, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.
How did the market react to Polaryx Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 4%, changed from $2.50 before the earnings release to $2.60 the day after.
When is Polaryx Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Polaryx Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Polaryx Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.